Open AccessInhibition of Src with AZD0530 Reveals the Src-Focal Adhesion Kinase Complex as a Novel Therapeutic Target in Papillary and Anaplastic Thyroid Cancer
Author(s) -
Rebecca E. Schweppe,
Anna A. Kerege,
Jena D. French,
Vibha Sharma,
Rachel L. Grzywa,
Bryan R. Haugen
Publication year - 2009
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2008-2511
Subject(s) - proto oncogene tyrosine protein kinase src , focal adhesion , cancer research , thyroid cancer , paxillin , tyrosine kinase , anaplastic thyroid cancer , phosphorylation , chemistry , microbiology and biotechnology , biology , cancer , medicine , signal transduction
Focal adhesion kinase (FAK) and Src are overexpressed and activated in many cancers and have been associated with tumor progression. The role of the Src-FAK complex has not been characterized in papillary and anaplastic thyroid cancer (PTC and ATC).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom